Hangzhou Diagens Biotechnology Co., Ltd. (2526.HK) Stock Overview
Explore Hangzhou Diagens Biotechnology Co., Ltd.’s financial performance, market position, analyst ratings, and future outlook.
Hangzhou Diagens Biotechnology Co., Ltd. (2526.HK)
Key Financials
Key Financials
Market Cap
32.9B
P/E Ratio
N/A
EPS (TTM)
$-0.88
ROE
N/A
2526.HK Stock Analysis & Investment Overview (HKSE)
Our AI-powered analysis of Hangzhou Diagens Biotechnology Co., Ltd. (HKSE: 2526.HK) gives investors deep insight into how the stock performs on the HKSE exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Hangzhou Diagens Biotechnology Co., Ltd.'s HKSE-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of 2526.HK on the HKSE shows an RSI of 53.57, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $159.85 for the HKSE listing.
Key metrics behind Hangzhou Diagens Biotechnology Co., Ltd.'s HKSE-traded stock include a P/E ratio of N/A and a market capitalization of 32.9B. Combined with our AI analysis, these give both institutional and retail investors a clear view of 2526.HK on the HKSE.